logo
Dr. Stefanie Flückiger-Mangual
Finalist

Finalist Young Entrepreneur of the year

Dr. Stefanie Flückiger-Mangual

Co-Founder & CEO, TOLREMO therapeutics AG

Dr. Stefanie Flückiger-Mangual is co-founder and CEO of TOLREMO therapeutics AG, which was founded in 2017. TOLREMO is a spin-off from ETH Zurich and is developing a new type of booster drug with the aim of increasing the efficacy of anti-cancer drugs. The first molecule developed by TOLREMO is currently being tested in an international clinical trial in cancer patients. 

Stefanie Flückiger holds a Bachelor's degree in Biomedicine from the University of Fribourg and a Master's degree in Biochemistry from ETH Zurich. She completed her PhD at ETH, specialising in cancer drug resistance mechanisms. After completing her PhD, she worked as a postdoc at ETH, where she laid the scientific foundations for the subsequent founding of TOLREMO.

To provide you with the best possible experience, we use technologies such as cookies to store and/or access device information. If you agree to these technologies, we may process data such as browsing behavior or unique IDs on this website. If you do not share or withdraw your consent, certain features and functionality may be affected.